Respiratory cytology in the era of molecular diagnostics: A review

Diagnostic Cytopathology

Volumn 40, Issue 6, 2012, Pages 556-563

  Witt, Benjamin L ^a   Wallander, Michelle L ^b   Layfield, Lester J ^a   Hirschowitz, Sharon ^c  

^a ARUP LABORATORIES   (United States)

^b ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

bronchial washings; FNA; molecular testing; mutational analysis; respiratory cytology

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; CYTOKERATIN 3; CYTOKERATIN AE1; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; SYNAPTOPHYSIN;

APOPTOSIS; ASPIRATION BIOPSY; BRONCHUS MUCOSA; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER INVASION; CANCER PROGNOSIS; CARCINOMA IN SITU; CELL STRUCTURE; CHROMATIN; CHROMOSOME 2P; CONFERENCE PAPER; CYTOLOGY; CYTOPATHOLOGY; CYTOPLASM; ELECTRON MICROSCOPY; EXON; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE MUTATION; GENE REARRANGEMENT; HISTOPATHOLOGY; HUMAN; INFLAMMATION; LUNG ADENOCARCINOMA; LUNG ALVEOLUS EPITHELIUM; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; METASTASIS; MOLECULAR DIAGNOSIS; ONCOGENE K RAS; POINT MUTATION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMALL CELL CARCINOMA; SQUAMOUS CELL CARCINOMA; TUMOR DIFFERENTIATION; TUMOR LOCALIZATION;

CARCINOMA, SQUAMOUS CELL; CELL NUCLEUS; DNA MUTATIONAL ANALYSIS; EARLY DETECTION OF CANCER; GENE REARRANGEMENT; HUMANS; LUNG NEOPLASMS; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84861536687     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.22858     Document Type: Conference Paper

References (60)

1. Cancer Facts and Figures. American Cancer Society, Inc. Accessed on September 15, 2011.
2. Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011; 6: 244-285.
3. Ocque R, Tochigi N, Ohori NP, et al. Usefulness of immunohistochemical and histochemical studies in the classification of lung adenocarcinoma and squamous cell carcinoma in cytologic specimens. Am J Clin Pathol 2011; 136: 81-87.
4. Auger M, Katz RL, Johnston DA,. Differentiating cytological features of bronchioloalveolar carcinoma from adenocarcinoma of the lung in fine-needle aspirations: A statistical analysis of 27 cases. Diagn Cytopathol 1997; 16: 253-257.
5. Elson CE, Moore SP, Johnston WW,. Morphologic and immunocytochemical studies of bronchioloalveolar carcinoma at Duke University Medical Center, 1968-1986. Anal Quant Cytol Histol 1989; 11: 261-274.
6. Vattuone J, Cramer H,. Bronchiolalveolar carcinoma (BAC): Analysis of 40 fine needle aspiration (FNA) cytology cases. Acta Cytol 1999; 43: 937-938.
7. Saad RS, Silverman JF,. Respiratory cytology: Differential diagnosis and pitfalls. Diagn Cytopathol 2010; 38: 297-307.
8. Johnston WW,. Percutaneous fine needle aspiration biopsy of the lung. A study of 1,015 patients. Acta Cytol 1984; 28: 218-224.
9. Weisbrod GL, Cunningham I, Tao LC, et al. Small cell anaplastic carcinoma: cytological-histological correlations from percutaneous fine-needle aspiration biopsy. Can Assoc Radiol J 1987; 38: 204-208.
10. Renshaw AA, Voytek TM, Haja J, et al. Distinguishing small cell carcinoma from non-small cell carcinoma of the lung: Correlating cytologic features and performance in the College of American Pathologists Non-Gynecologic Cytology Program. Arch Pathol Lab Med 2005; 129: 619-623.
11. Mullins RK, Thompson SK, Coogan PS, et al. Paranuclear blue inclusions: an aid in the cytopathologic diagnosis of primary and metastatic pulmonary small-cell carcinoma. Diagn Cytopathol 1994; 10: 332-335.
12. Walker WP, Wittchow RJ, Bottles K, et al. Paranuclear blue inclusions in small cell undifferentiated carcinoma: A diagnostically useful finding demonstrated in fine-needle aspiration biopsy smears. Diagn Cytopathol 1994; 10: 212-215.
13. Lee TK, Horner RD, Silverman JF, et al. Implications of nuclear diameter in small cell lung carcinoma. Anal Quant Cytol Histol 1990; 12: 78-84.
14. Lee TK, Silverman JF, Horner RD, et al. Overlap of nuclear diameters in lung cancer cells. Anal Quant Cytol Histol 1990; 12: 275-278.
15. Kargi A, Gurel D, Tuna B,. The diagnostic value of TTF-1, CK 5/6, and p63 immunostaining in classification of lung carcinomas. Appl Immunohistochem Mol Morphol 2007; 15: 415-420.
16. Kasprzak A, Zabel M, Biczysko W,. Selected markers (chromogranin A, neuron-specific enolase, synaptophysin, protein gene product 9.5) in diagnosis and prognosis of neuroendocrine pulmonary tumours. Pol J Pathol 2007; 58: 23-33.
17. Shy SW, Lee WH, Chou MC, et al. Small cell lung carcinoma: Clinicopathological, immunohistochemical, and ultrastructural study. J Surg Oncol 1990; 45: 146-161.
18. Pandit D, Griffiths D, Edwards J,. Bronchial biopsies-In praise of an H&E section. Histopathology 2006; 49: 96-97.
19. Bedrossian CWM, Glick AD, Graham S,. Cytopathology and electron microscopy in the diagnosis of lung cancer by fine needle aspiration biopsy. Patologia 1984; 22: 367-386.
20. Bedrossian CWM, Bonsib S, Moran C,. Differential diagnosis between mesothelioma and adenocarcinoma: A multimodal approach based on immunocytochemistry and electron microscopy. Semin Diagn Pathol 1992; 9: 124-132.
21. Glatz K, Savic S, Glatz D, et al. An online quiz uncovers limitations of morphology in equivocal lung cytology. Cancer 2006; 108: 480-487.
22. Naryshkin S, Young NA,. Respiratory cytology: A review of non-neoplastic mimics of malignancy. Diagn Cytopathol 1993; 9: 89-97.
23. Stanley MW, Henry-Stanley MJ, Gajl-Peczalska KJ, et al. Hyperplasia of type II pneumocytes in acute lung injury. Cytologic findings of sequential bronchoalveolar lavage. Am J Clin Pathol 1992; 97: 669-677.
24. Zaman SS, van Hoeven KH, Slott S, et al. Distinction between bronchioloalveolar carcinoma and hyperplastic pulmonary proliferations: A cytologic and morphometric analysis. Diagn Cytopathol 1997; 16: 396-401.
25. Naryshkin S, Bedrossian CW,. Selected mimics of malignancy in sputum and bronchoscopic cytology specimens. Diagn Cytopathol 1995; 13: 443-447.
26. Schrump DS, Giacone G, Kelsey RL, et al. Non-small cell lung cancer. In:, DeVita TL VT, Rosenberg SA, editors. Cancer principles and practive of oncology. Philadelphia: Wolters Kluwer; Lippincott, Williams and Wilkins; 2008. p 887-895.
27. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005; 23: 5900-5909.
28. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363: 1693-1703.
29. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
30. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-2388.
31. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
32. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101: 13306-13311.
33. Zhou C, Wu Y-L, Chen G, et al. Efficacy results from the randomized phase III OPTIMAL (CTOG 0802) study comparing first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM) in Chinese advanced cancer non-small cell lung cancer (NSCLC) patients (PTS) with EGFR activating mutations. Ann Oncol 2010; 21: viii1-viii2.
34. Sanders HR, Albitar M,. Somatic mutations of signaling genes in non-small-cell lung cancer. Cancer Genet Cytogenet 2010; 203: 7-15.
35. Zhu CQ, da Cunha Santos G, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008; 26: 4268-4275.
36. Benesova L, Minarik M, Jancarikova D, et al. Multiplicity of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors. Anticancer Res 2010; 30: 1667-1671.
37. Mascaux C, Iannino N, Martin B, et al. The role of RAS oncogene in survival of patients with lung cancer: A systematic review of the literature with meta-analysis. Br J Cancer 2005; 92: 131-139.
38. Gautschi O, Huegli B, Ziegler A, et al. Origin and prognostic value of circulating KRAS mutations in lung cancer patients. Cancer Lett 2007; 254: 265-273.
39. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005; 2: e17.
40. Raponi M, Winkler H, Dracopoli NC,. KRAS mutations predict response to EGFR inhibitors. Curr Opin Pharmacol 2008; 8: 413-418.
41. Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011; 29: 2866-2874.
42. Riely GJ, Marks J, Pao W,. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 2009; 6: 201-205.
43. Rodig SJ, Mino-Kenudson M, Dacic S, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009; 15: 5216-5223.
44. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561-566.
45. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009; 27: 4247-4253.
46. Takeuchi K, Choi YL, Togashi Y, et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 2009; 15: 3143-3149.
47. Togashi Y, Soda M, Sakata S, et al. KLC1-ALK: A novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. PLoS One 2012; 7: e31323.
48. Camidge DR, Kono SA, Flacco A, et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res 2010; 16: 5581-5590.
49. Wallander ML, Geiersbach KB, Tripp SR, Layfield LJ,. Comparison of RT-PCR, immunohistochemistry and fluorescence in situ hybridization methodologies for detection of EML4-ALK fusion positive non-small cell lung carcinoma: Implications for optimal clinical testing. Arch Pathol Lab Med, in press.
50. Smouse JH, Cibas ES, Janne PA, et al. EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer. Cancer 2009; 117: 67-72.
51. Han HS, Lim SN, An JY, et al. Detection of EGFR mutation status in lung adenocarcinoma specimens with different proportions of tumor cells using two methods of differential sensitivity. J Thorac Oncol 2012; 7: 355-364.
52. Betz BL, Roh MH, Weigelin HC, et al. The application of molecular diagnostic studies interrogating EGFR and KRAS mutations to stained cytologic smears of lung carcinoma. Am J Clin Pathol 2011; 136: 564-571.
53. Suda K, Tomizawa K, Mitsudomi T,. Biological and clinical significance of KRAS mutations in lung cancer: An oncogenic driver that contrasts with EGFR mutation. Cancer Metastasis Rev 2010; 29: 49-60.
54. Martelli MP, Sozzi G, Hernandez L, et al. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol 2009; 174: 661-670.
55. Sanders HR, Li HR, Bruey JM, et al. Exon scanning by reverse transcriptase-polymerase chain reaction for detection of known and novel EML4-ALK fusion variants in non-small cell lung cancer. Cancer Genet 2011; 204: 45-52.
56. Choi YL, Takeuchi K, Soda M, et al. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res 2008; 68: 4971-4976.
57. Takeuchi K, Choi YL, Soda M, et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res 2008; 14: 6618-6624.
58. Shaw AT, Solomon B, Kenudson MM,. Crizotinib and testing for ALK. J Natl Compr Cancer Netw 2011; 9: 1335-1341.
59. Mino-Kenudson M, Chirieac LR, Law K, et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res 2010; 16: 1561-1571.
60. Paik JH, Choe G, Kim H, et al. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. J Thorac Oncol 2011; 6: 466-472.